Exciting new developments in proton therapy treatments

PDL1 expression in thymic tumours

Exciting update on the Repurposing Drugs in Oncology (ReDO) project

PM1183 plus doxorubicin shows interesting activity in small cell lung cancer

Round-up of the latest research on lung cancer

Lenvatinib increases progression free survival when used with everolimus in metastatic renal cell carcinoma

Medically under-represented populations: Refining the calculation of accrual targets

Enzalutamide preferable to bicalutamide plus LHRH analogue in prostate cancer

Screening to identify unsuitable candidates for ipilimumab in advanced melanoma

Nivolumab alone superior to ipilimumab alone in advanced melanoma

Extended adjuvant therapy for HER2-positive early breast cancer

New dexamethasone combination yields two-fold improvement in median PFS in multiple myeloma

Preliminary analysis on the RNA sequencing data of lung squamous cell carcinoma

Survival benefits following eribulin in advanced liposarcoma and leiomyosarcoma

ASCO 2015: Latest developments in multiple myeloma

Adjuvant denosumab may preserve bone health in postmenopausal breast cancer patients: results of the ABCSG-18 trial

Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer

ASCO 2015: Latest in chronic lymphocytic leukaemia

Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma

Subgroup analysis of molecular markers in phase III study of high risk low-grade glioma

Initial nivolumab-based treatment halts melanoma progression

Comment: Eribulin extends overall survival for advanced liposarcoma and leiomyosarcoma

New intelligence network that supports efforts to improve quality of care and development of new medicines

Non-randomised clinical trial aims to describe the safety and efficacy of commercially available, targeted anticancer drugs

Advanced DNA sequencing test used to match rare cancers

Developments in clinical trials and health information technology that will improve targeted therapies for patients

Dasatinib plus intensive chemo versus stem cell transplant for Philadelphia chromosome positive ALL

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Raloxifene retained approximately 81% of the effectiveness of tamoxifen in preventing invasive breast cancer

Next generation inhibitors help overcome problems of resistance in ALK positive lung cancer

Transarterial chemoembolization with or without sorafenib for intermediate-stage hepatocellular carcinoma

Letrozole vs observation for HR positive breast cancer

Comment: Nivolumab-based treatment halts melanoma progression

Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases

Preventive neck lymph node surgery improves early oral cancer survival

Preventive neck lymph node surgery improves early oral cancer survival

Risks of adjuvant whole brain radiation therapy outweigh benefits for patients with limited brain metastases

Improved care has extended lifespan of childhood cancer survivors since the 1970s

Phase III study finds initial nivolumab-based treatment halts melanoma progression

Improved care has extended lifespan of childhood cancer survivors since the 1970s

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Ibrutinib combination regimen shows substantial benefits in relapsed CLL

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Extensive lymph node surgery may not be necessary for some patients with melanoma

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma

Extensive lymph node surgery may not be necessary for some patients with melanoma

First effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proves effective for easing symptoms of myelofibrosis

New ibrutinib combination regimen shows substantial benefits in relapsed chronic lymphocytic leukaemia

Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

First-in-class targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Immunotherapy developments in lung, head and neck, liver and PD-1 repsonse prediction

Pembrolizumab for head and neck cancer

Genomic marker predicts anti-PD-1 response in several cancers

Nivolumab extends survival for NSCLC

Promising results for nivolumab in advanced liver cancer

Nivolumab extends survival for patients with the most common lung cancer

Pembrolizumab shows promising activity against head and neck cancer

Nivolumab shows highly promising activity in advanced liver cancer in early-stage trial

Genomic marker predicts anti-PD-1 response in several cancers